CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma

Abstract Polybromo 1 (PBRM1) inactivating mutations are associated with clinical benefit from immune checkpoint inhibitor treatments in clear cell renal cell carcinoma (ccRCC). However, whether targeting PBRM1 has the potential to enhance immunotherapy efficacy in patients with wild‐type PBRM1 and t...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Advanced Science
المؤلفون الرئيسيون:	Yizeng Fan, Weichao Dan, Taotao Que, Yi Wei, Bo Liu, Zixi Wang, Yulin Zhang, Yuzhao Wang, Tianjie Liu, Yanxin Zhuang, Mengxing Li, Chendong Guo, Jin Zeng, Bohan Ma, Lei Li
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wiley 2025-02-01
الموضوعات:	CDC20 Immunotherapy p62 PBRM1 RCC
الوصول للمادة أونلاين:	https://doi.org/10.1002/advs.202412967